3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Prostatic Neoplasms
3
Herpes Zoster
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Uterine Cervical Dysplasia
2
Papillomavirus Infections
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Influenza, Human
2
Glioblastoma
2
Whooping Cough
1
Waldenstrom Macroglobulinemia
1
Tetanus
1
Spondylitis, Ankylosing
1
Psoriasis
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Glandular and Epithelial
1
Multiple Myeloma
1
Meningitis
1
Medulloblastoma
1
Hematologic Neoplasms
1
Glioma
1
Diphtheria
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Crohn Disease
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Interventions
Rituximab
49
fludarabine phosphate
32
Cyclophosphamide
30
Whole-Body Irradiation
26
Peripheral Blood Stem Cell Transplantation
25
Mycophenolic Acid
24
Tacrolimus
19
Cyclosporine
16
Dexamethasone
13
Busulfan
13
ibrutinib
12
Sirolimus
12
Bortezomib
11
Antilymphocyte Serum
11
Melphalan
10
Etoposide
10
Calcium Dobesilate
10
Methotrexate
8
Lenalidomide
8
Cyclosporins
8
idelalisib
7
Everolimus
6
Indium
5
Filgrastim
5
thymoglobulin
4
ibritumomab tiuxetan
4
carfilzomib
4
Vincristine
4
Prednisone
4
In Situ Hybridization, Fluorescence
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Waldenstrom Macroglobulinemia
×
Vaccines
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts